Protein pathways provide clues in leukemia research
New research by scientists at Rice University and the University of Texas MD Anderson Cancer Center profiles protein pathways distinctive to certain leukemia patients. The graphic shows interacting proteins in leukemia cells that can be characterized by networks analogous to highways. (Qutub Lab/Rice University)
Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease.
With their new method, Rice bioengineer Amina Qutub, MD Anderson clinician and scientist Steven Kornblau and Rice graduate student Heather York analyzed more than a decade's worth of data. They identified patterns in the expression of 203 proteins studied in cells of acute myeloid leukemia (AML) patients and found nearly 700 protein pairs (from among thousands of possibilities) implicated in such networks.
The goal is to fine-tune therapy for patients, Qutub said. If it's possible to know the protein signaling pathways of particular types of leukemia, she said, then drugs may be found or designed to target the disease by blocking those pathways.
"Leukemia is not just one disease," said Qutub, who attended Rice as an undergraduate and is now an assistant professor of bioengineering based at Rice's BioScience Research Collaborative. "It's many, many diseases lumped into one category. You can't use a sledgehammer approach to treat it, though that's what clinicians have been doing."
"A Phillips head screwdriver does great if you've got a cross on your screw head," Kornblau said. "It doesn't work very well if you've got a slot. Companies have drugs that might work gangbusters in a small fraction of patients, but if you study a large aggregate, it doesn't look like a very active agent. Ideally, if it works in 5 percent of patients and you can pick them out ahead of time, you put them on the right drug and spare the other 95 percent from getting a drug that is not going to help them."
It's not unusual for leukemia patients to go into remission, Qutub said, but most suffer a relapse within two years. "We're trying to figure out what's so different about these patients, and whether we can enhance their therapy. The only way we know to do that is to figure out the protein signature."
Proteins are the workhorses of the cell. Created from blueprints stored in DNA, they pass chemical signals from one to another with instructions on just about every activity a cell is capable of. But when their basic coding is scrambled, they can just as easily cause a cell to self-destruct.
Qutub likened protein signaling pathways to city traffic. "You might take a train, drive a car, walk or take a bicycle, but eventually you would get to your location," she said. "In cancer patients, protein pathways seem to follow patterns. In normal cells, there are predominant pathways, and while you may have the same pathways in cancer cells, they might also have alternate routes and take them, to varying degrees."
Specific routes proteins use to pass signals may be the key to determining their type, so it was worth investigating a treasure trove of data that had been gathered from MD Anderson patients, Qutub said.
The project began with a chance meeting by Qutub and Kornblau at a conference in Colorado on hypoxia. "Steve said, 'You're working with mathematical modeling of hypoxic response. I have a patient set I think you might be interested in.' That's how it started, and it took us down a very different road, using machine-learning algorithms and statistical techniques that hadn't been part of my core research but have now become integral to both this project and other research in the lab," Qutub said.
The World Health Organization had categorized AML patients by certain cell phenotypes, Qutub said, "but very little had been done at the protein level. Our clinical collaborators had started genetic and proteomic studies a while back and identified recurrent patterns of protein expression, some of which were associated with recurrent chromosomal changes like 'inv (16),' the inversion of chromosome 16, or 't(8;21),' which is the transpose of the 8 and 21 chromosomes." They are found in about 15 percent of patients with AML, she said.
"Patients with these two chromosomal changes respond more favorably to current AML therapy," Kornblau said, "and the genes from each of these genetic abnormalities are involved in the same transcription factor complex, creating a mechanistic link. But despite this mechanistic link, they differ in some clinical features and outcome."
Kornblau's data was precisely what Qutub and her group needed. They targeted inv (16) and t(8;21) to learn what protein pathways were common to both of these cytogenetic categories, what might explain their increased responsiveness and what changes were unique to each that might explain their clinical differences. From the mass of data more than 20,000 possible protein pairs they found that 678 pairs related to inv (16) and t(8;21) were significantly different compared with normal cells.
"There are some genetic markers that are definitely associated with a prognosis of leukemia," Qutub said. "And other things can cause leukemia -- acute myeloid in particular -- perhaps even chemotherapy itself. The way cancer patients are treated may be causing mutations and in turn triggering leukemic response."
With their analytical method tried and tested, Qutub and her team can now statistically group patients who present with particular protein pathways by age, gender, therapies and other criteria, and then take a closer look at protein signaling pathways in bone marrow-derived stem cells, a prime suspect in patients who relapse even after decades of remission. "We think something has to be unique about stem cells," she said.
The key problem with all cancers, including leukemia, is their plasticity, she said. "Cancer has multiple ways of getting to the same destination. You try one drug, and cancer's going to circumvent you and go a different way. What we're trying to say is, 'Here are all the possible ways,' so we can begin to target the intersections."
More information: Read the abstract at onlinelibrary.wile… 491/abstract
Journal reference: Proteomics
Provided by Rice University
- Two-faced leukemia? Dec 12, 2011 | not rated yet | 0
- Gene mutation improves leukemia drug's effect Jun 17, 2008 | not rated yet | 0
- Kidney cancer drug attacks a major type of acute myeloid leukemia Jan 29, 2008 | not rated yet | 0
- Protein that predicts prognosis of leukemia patients may also be a therapeutic target Jul 08, 2010 | not rated yet | 0
- Discovery of Mer protein in leukemia cells' nuclei may be new, druggable target Mar 13, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
13 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...
Cancer 9 minutes ago | not rated yet | 0
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...
Cancer 13 minutes ago | not rated yet | 0
Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...
Cancer 1 hour ago | not rated yet | 0 |
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...
Cancer 5 hours ago | not rated yet | 0
Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.
Cancer 5 hours ago | not rated yet | 0 |
(HealthDay)—A shortage of a critical tuberculosis drug has hampered the efforts of health departments across the United States to contain the spread of the highly infectious lung disease, federal officials ...
13 minutes ago | not rated yet | 0
Maintaining a heart healthy lifestyle may also help protect chronic kidney disease patients from developing kidney failure and dying prematurely, according to a study appearing in an upcoming issue of the Journal of the Am ...
33 minutes ago | not rated yet | 0
Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies ...
10 minutes ago | not rated yet | 0
Don't doubt it when a woman harried by hot flashes says she's having a hard time remembering things. A new study published online in Menopause, the journal of The North American Menopause Society (NAMS), helps confirm with o ...
12 minutes ago | not rated yet | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
53 minutes ago | not rated yet | 0